Cambridge, Massachusetts Thursday, October 17, 2024, 17:00 Hrs [IST] ...

Cullinan Therapeutics has filed an investigational new drug application with the U.S. Food and Drug Administration (FDA) for CLN-978 for the treatment of systemic lupus erythematosus (SLE). Continue ...

Cullinan Therapeutics said the U.S. Food and Drug Administration approved its investigation new drug application for CLN-978, a potential treatment for lupus. The biopharmaceutical company said the ...

Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) has received a consensus recommendation of “Buy” from the six ratings firms that are covering the firm, MarketBeat Ratings reports.

Sept. 17, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today received Human Research ...

Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) have been assigned a consensus rating of “Buy” from the six ratings firms that are currently covering the stock ...

The Human Research Ethics Committee (HREC) in Australia has granted clearance for Cullinan Therapeutics to commence an ...

Sept. 14, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today shared updated data in ...

BTIG analyst Julian Harrison reiterated a Buy rating on Outlook Therapeutics (OTLK – Research Report) today and set a price target of ...

CAMBRIDGE, Mass. - Cullinan Therapeutics, Inc. (NASDAQ: CGEM), a biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) to proceed with Phase 1 clinical trials ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.